Shorla Oncology has unveiled a groundbreaking drug, SH-105, designed to address breast and ovarian cancer.
SH-105 marks a significant advancement as it offers a ready-to-dilute alternative to a long-standing drug traditionally available in freeze-dried powder. The liquid formulation of SH-105 eliminates the requirement for reconstitution of the powder, leading to improved efficiency.
This innovation not only streamlines the preparation process but also mitigates the risks associated with the intricate steps involved in powder reconstitution. The transition to a liquid form is poised to enhance the overall convenience and safety of administering the drug.
The groundbreaking drug, SH-105, is set to provide hospital pharmacists and patients with access to a distinct ready-to-administer injectable product. With its unique characteristics, SH-105 is anticipated to streamline adoption swiftly once it receives approval.
According to the American Cancer Society, over 350,000 women are projected to receive a breast cancer diagnosis in the U.S. in 2023. SH-105 stands out among the numerous oncology drugs progressing through advanced pipeline.
This innovation offers a differentiated solution, ensuring convenience for both healthcare professionals and patients.
